On June 9, the Summer House reunion gave America a pharmacology lesson. West Wilson sat across from a furious cast and barely moved. Andy Cohen finally asked what everyone watching was thinking: "No offense, are you on a bunch of beta blockers or what?"
He was. The sharpest response came from inside the cast. Ciara Miller, a registered nurse, cut through it in a sentence: beta blockers don't remove emotion, they put your fight-or-flight symptoms "on DND." The pills could quiet a racing heart. They could not explain a lack of remorse.
That distinction, between calming the body and accounting for the feeling, is the whole story. And it is a story wellness brands should watch, because the discourse was never really about the drug. It was about whether calm can be trusted. Our social listening data shows consumers have been answering that question for two years, mostly in a different aisle. It is the clearest read yet on calm supplement consumer trends.
Anxiety is a fixture. Prescription calm is invisible.
Anxiety is one of the most durable subjects in wellness conversation. About 1 in every 65 posts in our corpus touches it, a share that has held steady for two years. It is not a trend. It is background radiation.
Beta blockers barely register. Across the same two years they held a share of conversation near 1 in every 100,000 wellness posts, roughly one-hundredth of ashwagandha's footprint. In July, the first full month after the reunion rippled outward, beta-blocker conversation reached its two-year high, roughly 1 in 18,000 posts.
That is still tiny. Part of the jump reflects a collection update on our side, so we read it as directional. Even at its cultural peak, the molecule at the center of a national conversation stayed a rounding error in wellness social.
Even at its cultural peak, the molecule at the center of a national conversation stayed a rounding error in wellness social.
Where anxiety actually shops: the calm stack
The anxiety conversation shops in what we call the calm stack, and it has been quietly booming.
Magnesium glycinate roughly tripled its share of conversation year over year, and it climbs steadily every quarter, not in one lucky spike.
L-theanine is up about 54% year over year.
Ashwagandha is up about 40% and now appears in roughly 1 in every 900 wellness posts, the largest of the three.
The pattern matters more than any single number. This is not a spike tied to a viral moment. It is a slow, compounding migration of everyday anxiety management into ingredients consumers can buy without a prescription, quarter after quarter, for two straight years.
The demand signal was never the scandal. That conversation was growing long before Andy Cohen said the words on camera.
The trust texture: reluctance and sequencing
Read the posts where beta blockers appear and a consistent texture shows up. Most are people managing real conditions with their doctors: racing hearts, migraines, thyroid flare-ups. Trust in the prescriber is real, but it is granted reluctantly and rationed carefully.
One consumer described pushing for tests before accepting a prescription:
"I asked for a blood test or ecg just to rule things out and was told I could have an ECG 'but when it came back as nothing you can try beta blockers."
She switched doctors, found an iron and B12 deficiency, and started with vitamins first.
That is the wellness market in miniature.
Consumers are not choosing between supplements and medicine. They are sequencing them, and the supplement aisle is where the sequence starts.
The reluctance runs deep. Alongside the sequencing, the posts carry a steady undertone of fear: fear of side effects, fear of dependence, fear of what a symptom might mean. One person put the hesitation plainly, saying they "get nervous before starting something new." That nervousness is the emotional backdrop every calm brand is selling into.
Marketers have noticed. Within weeks of the reunion, wellness creators were using propranolol as an opening hook before steering audiences toward a root-cause alternative. The trust consumers place in medication is already being borrowed as a sales device.
What this means for brands
Calm is a claim, and claims get fact-checked. The most trusted voice in the whole discourse was not a celebrity or a brand. It was a nurse with a mechanism: this is what the drug does to your body, this is what it cannot do to your feelings. Brands selling calm should hold themselves to the same specificity. Say what the ingredient does, in plain language, and what it does not.
Meet consumers in the fear, not after it. The texture around calm products is reluctance. Content that acknowledges the tradeoffs earns trust that glossy serenity imagery does not. And resist the urge to punch at pharma. The same consumers buying magnesium glycinate trust their prescribers; a brand that disparages the medication they rely on loses them.
Ride the stack, not the scandal. A newsjacked beta-blocker moment has a half-life of weeks. The durable signal is the calm stack's two-year climb, which is exactly where the share growth lives.
Building around the moment buys a spike. Building around the migration buys a category position.
West Wilson's calm failed on camera because nothing stood behind it. Audiences can tell performed calm from earned calm, and so can consumers. The brands winning the anxiety conversation are the ones doing on the shelf what he could not do on the couch: showing their work.
Want to see where calm-category demand is heading next? Talk to Brightfield Group about tracking it in real time.
Updated: 08/11/2026